The Japanese Lung Cancer Society Guideline for non-small cell lung cancer, stage IV

[1]  M. Socinski,et al.  IMpower131: Primary PFS and safety analysis of a randomized phase III study of atezolizumab + carboplatin + paclitaxel or nab-paclitaxel vs carboplatin + nab-paclitaxel as 1L therapy in advanced squamous NSCLC. , 2018, Journal of Clinical Oncology.

[2]  Xiangdong Zhou,et al.  Improvement in Overall Survival in a Randomized Study That Compared Dacomitinib With Gefitinib in Patients With Advanced Non-Small-Cell Lung Cancer and EGFR-Activating Mutations. , 2018, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[3]  Federico Cappuzzo,et al.  Atezolizumab for First‐Line Treatment of Metastatic Nonsquamous NSCLC , 2018, The New England journal of medicine.

[4]  A. Gemma,et al.  Phase III study comparing bevacizumab plus erlotinib to erlotinib in patients with untreated NSCLC harboring activating EGFR mutations: NEJ026. , 2018 .

[5]  A. Shaw,et al.  Lorlatinib in patients (Pts) with previously treated ALK+ advanced non-small cell lung cancer (NSCLC): Updated efficacy and safety. , 2018 .

[6]  T. Yamanaka,et al.  Erlotinib plus bevacizumab (EB) versus erlotinib alone (E) as first-line treatment for advanced EGFR mutation–positive non-squamous non–small-cell lung cancer (NSCLC): Survival follow-up results of JO25567. , 2018 .

[7]  A. Gemma,et al.  Phase III study comparing gefitinib monotherapy (G) to combination therapy with gefitinib, carboplatin, and pemetrexed (GCP) for untreated patients (pts) with advanced non-small cell lung cancer (NSCLC) with EGFR mutations (NEJ009). , 2018 .

[8]  Y. Shentu,et al.  Phase 3 study of carboplatin-paclitaxel/nab-paclitaxel (Chemo) with or without pembrolizumab (Pembro) for patients (Pts) with metastatic squamous (Sq) non-small cell lung cancer (NSCLC). , 2018 .

[9]  M. Socinski,et al.  Overall survival (OS) analysis of IMpower150, a randomized Ph 3 study of atezolizumab (atezo) + chemotherapy (chemo) ± bevacizumab (bev) vs chemo + bev in 1L nonsquamous (NSQ) NSCLC. , 2018 .

[10]  S. Novello,et al.  Pembrolizumab plus Chemotherapy in Metastatic Non–Small‐Cell Lung Cancer , 2018, The New England journal of medicine.

[11]  Ying Cheng,et al.  Osimertinib in Untreated EGFR‐Mutated Advanced Non–Small‐Cell Lung Cancer , 2018, The New England journal of medicine.

[12]  Thomas John,et al.  Osimertinib As First-Line Treatment of EGFR Mutation-Positive Advanced Non-Small-Cell Lung Cancer. , 2017, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[13]  A. Shaw,et al.  Lorlatinib in ALK- or ROS1-rearranged non-small cell lung cancer: an international, multicenter, open-label phase 1 trial , 2017, The Lancet. Oncology.

[14]  T. Mok,et al.  Randomized controlled trial of S-1 versus docetaxel in patients with non-small-cell lung cancer previously treated with platinum-based chemotherapy (East Asia S-1 Trial in Lung Cancer). , 2017 .

[15]  Ying Cheng,et al.  Dacomitinib versus gefitinib as first-line treatment for patients with EGFR-mutation-positive non-small-cell lung cancer (ARCHER 1050): a randomised, open-label, phase 3 trial. , 2017, The Lancet. Oncology.

[16]  M. Seike,et al.  Alectinib for Patients with ALK Rearrangement–Positive Non–Small Cell Lung Cancer and a Poor Performance Status (Lung Oncology Group in Kyushu 1401) , 2017, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

[17]  G. Scagliotti,et al.  Ceritinib versus chemotherapy in patients with ALK-rearranged non-small-cell lung cancer previously given chemotherapy and crizotinib (ASCEND-5): a randomised, controlled, open-label, phase 3 trial. , 2017, The Lancet. Oncology.

[18]  Young Hak Kim,et al.  Alectinib versus crizotinib in patients with ALK-positive non-small-cell lung cancer (J-ALEX): an open-label, randomised phase 3 trial , 2017, The Lancet.

[19]  Rafal Dziadziuszko,et al.  Alectinib versus Crizotinib in Untreated ALK‐Positive Non–Small‐Cell Lung Cancer , 2017, The New England journal of medicine.

[20]  Young Hak Kim,et al.  Updated efficacy and safety of the j-alex study comparing alectinib (ALC) with crizotinib (CRZ) in ALK-inhibitor naïve ALK fusion positive non-small cell lung cancer (ALK+ NSCLC). , 2017 .

[21]  Serafino Pantano,et al.  First-line ceritinib versus platinum-based chemotherapy in advanced ALK-rearranged non-small-cell lung cancer (ASCEND-4): a randomised, open-label, phase 3 study , 2017, The Lancet.

[22]  M. Ahn,et al.  Osimertinib or Platinum–Pemetrexed in EGFR T790M–Positive Lung Cancer , 2017, The New England journal of medicine.

[23]  V. Gebski,et al.  Checkpoint Inhibitors in Metastatic EGFR‐Mutated Non–Small Cell Lung Cancer—A Meta‐Analysis , 2017, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

[24]  Carlos Barrios,et al.  Atezolizumab versus docetaxel in patients with previously treated non-small-cell lung cancer (OAK): a phase 3, open-label, multicentre randomised controlled trial , 2017, The Lancet.

[25]  Yi-long Wu,et al.  A phase III randomised controlled trial of erlotinib vs gefitinib in advanced non-small cell lung cancer with EGFR mutations , 2017, British Journal of Cancer.

[26]  H. Groen,et al.  Dabrafenib plus trametinib in patients with previously untreated BRAFV600E-mutant metastatic non-small-cell lung cancer: an open-label, phase 2 trial. , 2016, The Lancet. Oncology.

[27]  Yi-long Wu,et al.  Maintenance erlotinib versus erlotinib at disease progression in patients with advanced non-small-cell lung cancer who have not progressed following platinum-based chemotherapy (IUNO study). , 2016, Lung cancer.

[28]  Y. Shentu,et al.  Pembrolizumab versus Chemotherapy for PD-L1-Positive Non-Small-Cell Lung Cancer. , 2016, The New England journal of medicine.

[29]  H. Groen,et al.  Multicenter Phase II Study of Whole-Body and Intracranial Activity With Ceritinib in Patients With ALK-Rearranged Non-Small-Cell Lung Cancer Previously Treated With Chemotherapy and Crizotinib: Results From ASCEND-2. , 2016, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[30]  Y. Hosomi,et al.  A randomized, double-blind, phase II study of ramucirumab plus docetaxel vs placebo plus docetaxel in Japanese patients with stage IV non-small cell lung cancer after disease progression on platinum-based therapy. , 2016, Lung cancer.

[31]  S. Digumarthy,et al.  EGFR Mutations and ALK Rearrangements Are Associated with Low Response Rates to PD-1 Pathway Blockade in Non–Small Cell Lung Cancer: A Retrospective Analysis , 2016, Clinical Cancer Research.

[32]  T. Yamanaka,et al.  Phase II study of crizotinib in east Asian patients (pts) with ROS1-positive advanced non-small cell lung cancer (NSCLC). , 2016 .

[33]  M. Fukuoka,et al.  Characteristics and overall survival of EGFR mutation-positive non-small cell lung cancer treated with EGFR tyrosine kinase inhibitors: a retrospective analysis for 1660 Japanese patients , 2016, Japanese journal of clinical oncology.

[34]  K. O'Byrne,et al.  Afatinib versus gefitinib as first-line treatment of patients with EGFR mutation-positive non-small-cell lung cancer (LUX-Lung 7): a phase 2B, open-label, randomised controlled trial. , 2016, The Lancet. Oncology.

[35]  Keunchil Park,et al.  Atezolizumab versus docetaxel for patients with previously treated non-small-cell lung cancer (POPLAR): a multicentre, open-label, phase 2 randomised controlled trial , 2016, The Lancet.

[36]  Y. Shentu,et al.  Pembrolizumab versus docetaxel for previously treated, PD-L1-positive, advanced non-small-cell lung cancer (KEYNOTE-010): a randomised controlled trial , 2016, The Lancet.

[37]  B. Han,et al.  Efficacy of EGFR tyrosine kinase inhibitors for non-adenocarcinoma lung cancer patients harboring EGFR-sensitizing mutations in China , 2016, Journal of Cancer Research and Clinical Oncology.

[38]  R. Govindan,et al.  Alectinib in Crizotinib-Refractory ALK-Rearranged Non-Small-Cell Lung Cancer: A Phase II Global Study. , 2016, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[39]  M. Socinski,et al.  Alectinib in ALK-positive, crizotinib-resistant, non-small-cell lung cancer: a single-group, multicentre, phase 2 trial. , 2016, The Lancet. Oncology.

[40]  M. Socinski,et al.  Isolating the Role of Bevacizumab in Elderly Patients With Previously Untreated Nonsquamous Non–Small Cell Lung Cancer , 2015, American journal of clinical oncology.

[41]  H. Groen,et al.  Dabrafenib plus trametinib in patients with previously treated BRAF(V600E)-mutant metastatic non-small cell lung cancer: an open-label, multicentre phase 2 trial. , 2016, The Lancet. Oncology.

[42]  T. Yamanaka,et al.  Nedaplatin plus docetaxel versus cisplatin plus docetaxel for advanced or relapsed squamous cell carcinoma of the lung (WJOG5208L): a randomised, open-label, phase 3 trial. , 2015, The Lancet. Oncology.

[43]  C. Rudin,et al.  Nivolumab versus Docetaxel in Advanced Nonsquamous Non-Small-Cell Lung Cancer. , 2015, The New England journal of medicine.

[44]  M. Socinski,et al.  3073 Exploratory analysis of frontline therapies in REVEL: A randomized phase III study of ramucirumab (RAM) plus docetaxel (DOC) versus DOC for the treatment of stage IV non-small-cell lung cancer (NSCLC) after disease progression on platinum-based therapy , 2015 .

[45]  Y. Hosomi,et al.  A prospective, multicentre phase II trial of low-dose erlotinib in non-small cell lung cancer patients with EGFR mutations pretreated with chemotherapy: Thoracic Oncology Research Group 0911. , 2015, European journal of cancer.

[46]  L. Crinò,et al.  Nivolumab versus Docetaxel in Advanced Squamous-Cell Non-Small-Cell Lung Cancer. , 2015, The New England journal of medicine.

[47]  L. Sequist,et al.  Clinical activity of afatinib in patients with advanced non-small-cell lung cancer harbouring uncommon EGFR mutations: a combined post-hoc analysis of LUX-Lung 2, LUX-Lung 3, and LUX-Lung 6. , 2015, The Lancet. Oncology.

[48]  Makoto Nishio,et al.  Phase I Study of Ceritinib (LDK378) in Japanese Patients with Advanced, Anaplastic Lymphoma Kinase-Rearranged Non–Small-Cell Lung Cancer or Other Tumors , 2015, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

[49]  H. Zhang,et al.  BEYOND: A Randomized, Double-Blind, Placebo-Controlled, Multicenter, Phase III Study of First-Line Carboplatin/Paclitaxel Plus Bevacizumab or Placebo in Chinese Patients With Advanced or Recurrent Nonsquamous Non-Small-Cell Lung Cancer. , 2015, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[50]  A. Gemma,et al.  A randomized phase III trial of oral S-1 plus cisplatin versus docetaxel plus cisplatin in Japanese patients with advanced non-small-cell lung cancer: TCOG0701 CATS trial , 2015, Annals of oncology : official journal of the European Society for Medical Oncology.

[51]  T. Lynch,et al.  Clinical outcomes in elderly patients with advanced non-small cell lung cancer: results from ARIES, a bevacizumab observational cohort study. , 2015, Clinical oncology (Royal College of Radiologists (Great Britain)).

[52]  N. Saijo,et al.  Randomized phase III trial comparing weekly docetaxel plus cisplatin versus docetaxel monotherapy every 3 weeks in elderly patients with advanced non-small-cell lung cancer: the intergroup trial JCOG0803/WJOG4307L. , 2015, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[53]  L. Sequist,et al.  Afatinib versus cisplatin-based chemotherapy for EGFR mutation-positive lung adenocarcinoma (LUX-Lung 3 and LUX-Lung 6): analysis of overall survival data from two randomised, phase 3 trials. , 2015, The Lancet. Oncology.

[54]  C. Obasaju,et al.  PRONOUNCE: Randomized, Open-Label, Phase III Study of First-Line Pemetrexed + Carboplatin Followed by Maintenance Pemetrexed versus Paclitaxel + Carboplatin + Bevacizumab Followed by Maintenance Bevacizumab in Patients ith Advanced Nonsquamous Non–Small-Cell Lung Cancer , 2014, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

[55]  F. Cappuzzo,et al.  First-line crizotinib versus chemotherapy in ALK-positive lung cancer. , 2014, The New England journal of medicine.

[56]  Jeffrey W. Clark,et al.  Crizotinib in ROS1-rearranged non-small-cell lung cancer. , 2014, The New England journal of medicine.

[57]  A. Rossi,et al.  Six versus fewer planned cycles of first-line platinum-based chemotherapy for non-small-cell lung cancer: a systematic review and meta-analysis of individual patient data. , 2014, The Lancet. Oncology.

[58]  Koichi Goto,et al.  Erlotinib alone or with bevacizumab as first-line therapy in patients with advanced non-squamous non-small-cell lung cancer harbouring EGFR mutations (JO25567): an open-label, randomised, multicentre, phase 2 study. , 2014, The Lancet. Oncology.

[59]  Ruey-min Lee,et al.  Safety and activity of alectinib against systemic disease and brain metastases in patients with crizotinib-resistant ALK-rearranged non-small-cell lung cancer (AF-002JG): results from the dose-finding portion of a phase 1/2 study. , 2014, The Lancet. Oncology.

[60]  Andreas Sashegyi,et al.  Ramucirumab plus docetaxel versus placebo plus docetaxel for second-line treatment of stage IV non-small-cell lung cancer after disease progression on platinum-based therapy (REVEL): a multicentre, double-blind, randomised phase 3 trial , 2014, The Lancet.

[61]  Masahiko Ando,et al.  Randomized phase III trial of erlotinib versus docetaxel as second- or third-line therapy in patients with advanced non-small-cell lung cancer: Docetaxel and Erlotinib Lung Cancer Trial (DELTA). , 2014, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[62]  William Pao,et al.  Using multiplexed assays of oncogenic drivers in lung cancers to select targeted drugs. , 2014, JAMA.

[63]  H. Groen,et al.  Maintenance bevacizumab-pemetrexed after first-line cisplatin-pemetrexed-bevacizumab for advanced nonsquamous nonsmall-cell lung cancer: updated survival analysis of the AVAPERL (MO22089) randomized phase III trial. , 2014, Annals of oncology : official journal of the European Society for Medical Oncology.

[64]  J. Engelman,et al.  Ceritinib in ALK-rearranged non-small-cell lung cancer. , 2014, The New England journal of medicine.

[65]  Yi-long Wu,et al.  Afatinib versus cisplatin plus gemcitabine for first-line treatment of Asian patients with advanced non-small-cell lung cancer harbouring EGFR mutations (LUX-Lung 6): an open-label, randomised phase 3 trial. , 2014, The Lancet. Oncology.

[66]  J-L Pretet,et al.  Rare EGFR exon 18 and exon 20 mutations in non-small-cell lung cancer on 10 117 patients: a multicentre observational study by the French ERMETIC-IFCT network. , 2014, Annals of oncology : official journal of the European Society for Medical Oncology.

[67]  C. Obasaju,et al.  PointBreak: a randomized phase III study of pemetrexed plus carboplatin and bevacizumab followed by maintenance pemetrexed and bevacizumab versus paclitaxel plus carboplatin and bevacizumab followed by maintenance bevacizumab in patients with stage IIIB or IV nonsquamous non-small-cell lung cancer. , 2013, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[68]  K. Goto,et al.  A prospective, phase II, open-label study (JO22903) of first-line erlotinib in Japanese patients with epidermal growth factor receptor (EGFR) mutation-positive advanced non-small-cell lung cancer (NSCLC). , 2013, Lung cancer.

[69]  Chun-Ming Tsai,et al.  Phase III study of afatinib or cisplatin plus pemetrexed in patients with metastatic lung adenocarcinoma with EGFR mutations. , 2013, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[70]  G. Giaccone,et al.  Erlotinib versus docetaxel as second-line treatment of patients with advanced non-small-cell lung cancer and wild-type EGFR tumours (TAILOR): a randomised controlled trial. , 2013, The Lancet. Oncology.

[71]  C. Gridelli,et al.  PARAMOUNT: Final overall survival results of the phase III study of maintenance pemetrexed versus placebo immediately after induction treatment with pemetrexed plus cisplatin for advanced nonsquamous non-small-cell lung cancer. , 2013, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[72]  C. Barrios,et al.  Randomized phase III trial of single-agent pemetrexed versus carboplatin and pemetrexed in patients with advanced non-small-cell lung cancer and Eastern Cooperative Oncology Group performance status of 2. , 2013, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[73]  Y. Ichinose,et al.  Phase II trial of erlotinib for Japanese patients with previously treated non-small-cell lung cancer harboring EGFR mutations: results of Lung Oncology Group in Kyushu (LOGiK0803). , 2013, Japanese journal of clinical oncology.

[74]  K. Kunimasa,et al.  How Sensitive Are Epidermal Growth Factor Receptor–Tyrosine Kinase Inhibitors for Squamous Cell Carcinoma of the Lung Harboring EGFR Gene–Sensitive Mutations? , 2013, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

[75]  J. Pignon,et al.  Systematic review and meta-analysis of randomised, phase II/III trials adding bevacizumab to platinum-based chemotherapy as first-line treatment in patients with advanced non-small-cell lung cancer. , 2013, Annals of oncology : official journal of the European Society for Medical Oncology.

[76]  A. Gemma,et al.  Updated overall survival results from a randomized phase III trial comparing gefitinib with carboplatin-paclitaxel for chemo-naïve non-small cell lung cancer with sensitive EGFR gene mutations (NEJ002). , 2013, Annals of oncology : official journal of the European Society for Medical Oncology.

[77]  C. Boshoff,et al.  First-line erlotinib in patients with advanced non-small-cell lung cancer unsuitable for chemotherapy (TOPICAL): a double-blind, placebo-controlled, phase 3 trial , 2012, The Lancet. Oncology.

[78]  S. Kudoh,et al.  First-Line Gefitinib in Patients Aged 75 or Older With Advanced Non–Small Cell Lung Cancer Harboring Epidermal Growth Factor Receptor Mutations: NEJ 003 Study , 2012, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

[79]  M. Socinski,et al.  Weekly nab-paclitaxel in combination with carboplatin versus solvent-based paclitaxel plus carboplatin as first-line therapy in patients with advanced non-small-cell lung cancer: final results of a phase III trial. , 2012, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[80]  K. Mori,et al.  Randomized phase II study of first-line carboplatin-paclitaxel with or without bevacizumab in Japanese patients with advanced non-squamous non-small-cell lung cancer. , 2012, Lung cancer.

[81]  A. Gemma,et al.  Quality of life with gefitinib in patients with EGFR-mutated non-small cell lung cancer: quality of life analysis of North East Japan Study Group 002 Trial. , 2012, The oncologist.

[82]  S. Toyooka,et al.  Updated overall survival results of WJTOG 3405, a randomized phase III trial comparing gefitinib (G) with cisplatin plus docetaxel (CD) as the first-line treatment for patients with non-small cell lung cancer harboring mutations of the epidermal growth factor receptor (EGFR). , 2012 .

[83]  E. Felip,et al.  Erlotinib versus standard chemotherapy as first-line treatment for European patients with advanced EGFR mutation-positive non-small-cell lung cancer (EURTAC): a multicentre, open-label, randomised phase 3 trial. , 2012, The Lancet. Oncology.

[84]  H. Groen,et al.  Safety and Efficacy of First-Line Bevacizumab Plus Chemotherapy in Elderly Patients with Advanced or Recurrent Nonsquamous Non-small Cell Lung Cancer: Safety of Avastin in Lung trial (MO19390) , 2012, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

[85]  S. Kobayashi,et al.  EGFR exon 20 insertion mutations in non-small-cell lung cancer: preclinical data and clinical implications. , 2012, The Lancet. Oncology.

[86]  Dae-Ho Lee,et al.  A Randomized Phase 3 Trial Comparing Pemetrexed/Carboplatin and Docetaxel/Carboplatin as First-Line Treatment for Advanced, Nonsquamous Non-small Cell Lung Cancer , 2011, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

[87]  B. Milleron,et al.  Carboplatin and weekly paclitaxel doublet chemotherapy compared with monotherapy in elderly patients with advanced non-small-cell lung cancer: IFCT-0501 randomised, phase 3 trial , 2011, The Lancet.

[88]  A. Sasse,et al.  Addition of Bevacizumab to Chemotherapy in Advanced Non-Small Cell Lung Cancer: A Systematic Review and Meta-Analysis , 2010, PloS one.

[89]  Jun Ma,et al.  Erlotinib versus chemotherapy as first-line treatment for patients with advanced EGFR mutation-positive non-small-cell lung cancer (OPTIMAL, CTONG-0802): a multicentre, open-label, randomised, phase 3 study. , 2011, The Lancet. Oncology.

[90]  Yukiko Nakamura,et al.  Efficacy of gefitinib for non‐adenocarcinoma non‐small‐cell lung cancer patients harboring epidermal growth factor receptor mutations: A pooled analysis of published reports , 2011, Cancer science.

[91]  J. Shih,et al.  Effectiveness of Tyrosine Kinase Inhibitors on “Uncommon” Epidermal Growth Factor Receptor Mutations of Unknown Clinical Significance in Non–Small Cell Lung Cancer , 2011, Clinical Cancer Research.

[92]  K. Kiura,et al.  Time trend in treatment-related deaths of patients with advanced non-small-cell lung cancer enrolled into phase III trials of systemic treatment. , 2011, Annals of oncology : official journal of the European Society for Medical Oncology.

[93]  N. Ikeda,et al.  Phase III trial comparing oral S-1 plus carboplatin with paclitaxel plus carboplatin in chemotherapy-naïve patients with advanced non-small-cell lung cancer: results of a west Japan oncology group study. , 2010, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[94]  A. Gemma,et al.  F1000 highlights , 2010 .

[95]  G. Giaccone,et al.  Erlotinib as maintenance treatment in advanced non-small-cell lung cancer: a multicentre, randomised, placebo-controlled phase 3 study. , 2010, The Lancet. Oncology.

[96]  R. Ramlau,et al.  Overall survival with cisplatin–gemcitabine and bevacizumab or placebo as first-line therapy for nonsquamous non-small-cell lung cancer: results from a randomised phase III trial (AVAiL) , 2010, Annals of oncology : official journal of the European Society for Medical Oncology.

[97]  S. Toyooka,et al.  Gefitinib versus cisplatin plus docetaxel in patients with non-small-cell lung cancer harbouring mutations of the epidermal growth factor receptor (WJTOG3405): an open label, randomised phase 3 trial. , 2010, The Lancet. Oncology.

[98]  S. Burdett.  Chemotherapy and supportive care versus supportive care alone for advanced non-small cell lung cancer. , 2008, The Cochrane database of systematic reviews.

[99]  Mariano Provencio,et al.  Screening for epidermal growth factor receptor mutations in lung cancer. , 2009, The New England journal of medicine.

[100]  K. Krejcy,et al.  Maintenance pemetrexed plus best supportive care versus placebo plus best supportive care for non-small-cell lung cancer: a randomised, double-blind, phase 3 study , 2009, The Lancet.

[101]  S. Kaasa,et al.  Phase III study by the Norwegian lung cancer study group: pemetrexed plus carboplatin compared with gemcitabine plus carboplatin as first-line chemotherapy in advanced non-small-cell lung cancer. , 2009, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[102]  A. Gemma,et al.  First-line gefitinib for patients with advanced non-small-cell lung cancer harboring epidermal growth factor receptor mutations without indication for chemotherapy. , 2009, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[103]  R. Gray,et al.  Retrospective evaluation of the clinical and radiographic risk factors associated with severe pulmonary hemorrhage in first-line advanced, unresectable non-small-cell lung cancer treated with Carboplatin and Paclitaxel plus bevacizumab. , 2009, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[104]  G. Scagliotti,et al.  The differential efficacy of pemetrexed according to NSCLC histology: a review of two Phase III studies. , 2009, The oncologist.

[105]  Johan Vansteenkiste,et al.  Phase III study comparing cisplatin plus gemcitabine with cisplatin plus pemetrexed in chemotherapy-naive patients with advanced-stage non-small-cell lung cancer. , 2008, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[106]  H. Kato,et al.  Interstitial lung disease in Japanese patients with lung cancer: a cohort and nested case-control study. , 2008, American journal of respiratory and critical care medicine.

[107]  R. Gray,et al.  Outcomes for elderly, advanced-stage non small-cell lung cancer patients treated with bevacizumab in combination with carboplatin and paclitaxel: analysis of Eastern Cooperative Oncology Group Trial 4599. , 2008, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[108]  Joon-Oh Park,et al.  Phase III trial of two versus four additional cycles in patients who are nonprogressive after two cycles of platinum-based chemotherapy in non small-cell lung cancer. , 2007, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[109]  M. Socinski,et al.  Third-Generation Chemotherapy Agents in the Treatment of Advanced Non-small Cell Lung Cancer: A Meta-Analysis , 2007, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

[110]  J. Crowley,et al.  Chemotherapy in Patients ≥80 with Advanced Non-small Cell Lung Cancer: Combined Results from SWOG 0027 and LUN 6 , 2007, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

[111]  M. Dimopoulos,et al.  Gemcitabine versus Gemcitabine–Carboplatin for Patients with Advanced Non-small Cell Lung Cancer and a Performance Status of 2: A Prospective Randomized Phase II Study of the Hellenic Cooperative Oncology Group , 2007, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

[112]  David H. Johnson,et al.  Randomized phase II trial of paclitaxel plus carboplatin or gemcitabine plus cisplatin in Eastern Cooperative Oncology Group performance status 2 non-small-cell lung cancer patients: ECOG 1599. , 2007, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[113]  N. Saijo,et al.  Randomized phase III study of cisplatin plus irinotecan versus carboplatin plus paclitaxel, cisplatin plus gemcitabine, and cisplatin plus vinorelbine for advanced non-small-cell lung cancer: Four-Arm Cooperative Study in Japan. , 2006, Annals of oncology : official journal of the European Society for Medical Oncology.

[114]  Robert Gray,et al.  Paclitaxel-carboplatin alone or with bevacizumab for non-small-cell lung cancer. , 2006, The New England journal of medicine.

[115]  R. Bremnes,et al.  Palliative chemotherapy beyond three courses conveys no survival or consistent quality-of-life benefits in advanced non-small-cell lung cancer , 2006, British Journal of Cancer.

[116]  M. Fukuoka,et al.  Phase III study of docetaxel compared with vinorelbine in elderly patients with advanced non-small-cell lung cancer: results of the West Japan Thoracic Oncology Group Trial (WJTOG 9904). , 2006, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[117]  M. Fukuoka,et al.  Predictive factors for interstitial lung disease, antitumor response, and survival in non-small-cell lung cancer patients treated with gefitinib. , 2006, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[118]  G. Hillerdal,et al.  Phase III trial of gemcitabine plus carboplatin versus single-agent gemcitabine in the treatment of locally advanced or metastatic non-small-cell lung cancer: the Swedish Lung Cancer Study Group. , 2005, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[119]  S. Barni,et al.  Pretreatment quality of life and functional status assessment significantly predict survival of elderly patients with advanced non-small-cell lung cancer receiving chemotherapy: a prognostic analysis of the multicenter Italian lung cancer in the elderly study. , 2005, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[120]  Renato Martins,et al.  Erlotinib in previously treated non-small-cell lung cancer. , 2005, The New England journal of medicine.

[121]  J. Holland,et al.  Single-agent versus combination chemotherapy in advanced non-small-cell lung cancer: the cancer and leukemia group B (study 9730). , 2005, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[122]  David M Jablons,et al.  Randomized phase II trial comparing bevacizumab plus carboplatin and paclitaxel with carboplatin and paclitaxel alone in previously untreated locally advanced or metastatic non-small-cell lung cancer. , 2004, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[123]  Miklos Pless,et al.  Randomized phase III trial of pemetrexed versus docetaxel in patients with non-small-cell lung cancer previously treated with chemotherapy. , 2004, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[124]  C. Gridelli,et al.  Treatment of advanced non-small-cell lung cancer patients with ECOG performance status 2: results of an European Experts Panel. , 2004, Annals of oncology : official journal of the European Society for Medical Oncology.

[125]  A. Rossi,et al.  Chemotherapy for elderly patients with advanced non-small-cell lung cancer: the Multicenter Italian Lung Cancer in the Elderly Study (MILES) phase III randomized trial. , 2003, Journal of the National Cancer Institute.

[126]  T. Mukohara,et al.  Japanese experience with second-line chemotherapy with low-dose (60 mg/m2) docetaxel in patients with advanced non-small-cell lung cancer , 2001, Cancer Chemotherapy and Pharmacology.

[127]  R. Stephens,et al.  Gemcitabine plus best supportive care (BSC) vs BSC in inoperable non-small cell lung cancer – a randomized trial with quality of life as the primary outcome , 2000, British Journal of Cancer.

[128]  M. Kris,et al.  Randomized Phase III Trial of Docetaxel Versus Vinorelbine or Ifosfamide in Patients With Advanced Non–Small-Cell Lung Cancer Previously Treated With Platinum-Containing Chemotherapy Regimens , 2000 .

[129]  J. Dancey,et al.  Prospective randomized trial of docetaxel versus best supportive care in patients with non-small-cell lung cancer previously treated with platinum-based chemotherapy. , 2000, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[130]  M. Kris,et al.  Randomized phase III trial of docetaxel versus vinorelbine or ifosfamide in patients with advanced non-small-cell lung cancer previously treated with platinum-containing chemotherapy regimens. The TAX 320 Non-Small Cell Lung Cancer Study Group. , 2000, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[131]  G. Luporini,et al.  Effects of vinorelbine on quality of life and survival of elderly patients with advanced non-small-cell lung cancer. The Elderly Lung Cancer Vinorelbine Italian Study Group. , 1999, Journal of the National Cancer Institute.